Archive

NEJM Study Adds to Overwhelming Evidence on Hospital Markups ... and the Need for 340B Reform

NEJM Study Adds to Overwhelming Evidence on Hospital Markups ... and the Need for 340B Reform

Plus: am I naive for being amazed that Optum is making loans to health care providers?

Brian Reid
Brian Reid
Tyson Foods Ditches Their Mega-PBM In Favor of an Upstart 'To Really Get a Partner'

Tyson Foods Ditches Their Mega-PBM In Favor of an Upstart 'To Really Get a Partner'

And I'm still stuck on the Arnold Ventures net-price denialism

Brian Reid
Brian Reid
BioCentury Goes Deep on How Arnold Ventures Shaped the IRA ... and Where It's Going Next

BioCentury Goes Deep on How Arnold Ventures Shaped the IRA ... and Where It's Going Next

Plus a must-read letter to the CBO from No Patient Left Behind

Brian Reid
Brian Reid
Looking at Which 2022 Drug Approvals Received the Most Attention Around Pricing

Looking at Which 2022 Drug Approvals Received the Most Attention Around Pricing

Plus some musings on why news-you-can-use around drug pricing is so often shallow

Brian Reid
Brian Reid
The Reaction to a New Piece About Price Hikes Shows Why We Can't Have Nice Things

The Reaction to a New Piece About Price Hikes Shows Why We Can't Have Nice Things

And Mark Cuban convinces me (mostly) that maybe transparency alone could fix the drug-price debate

Brian Reid
Brian Reid
The NYT's Off-the-Mark Explainer Is Making Smart Conversations on Drug Pricing Harder

The NYT's Off-the-Mark Explainer Is Making Smart Conversations on Drug Pricing Harder

Plus news on 340B, biosimilars, prior auth and more

Brian Reid
Brian Reid
The Breast Cancer Death Rate Is Way, Way Down. There's a Lesson In That.

The Breast Cancer Death Rate Is Way, Way Down. There's a Lesson In That.

Plus a good, if dispiriting, look at the state of access to a breakthrough postpartum depression pill

Brian Reid
Brian Reid
UnitedHealth Group Made $5.5 Billion Last Quarter, Even Though (or Maybe Because) Insurance Keeps Getting Worse

UnitedHealth Group Made $5.5 Billion Last Quarter, Even Though (or Maybe Because) Insurance Keeps Getting Worse

And a lot of Arnold Ventures-adjacent items, too

Brian Reid
Brian Reid
Valuing Obesity Drugs Isn't 'Clever' Or 'Depressing,' and Other #JPM24 Thoughts

Valuing Obesity Drugs Isn't 'Clever' Or 'Depressing,' and Other #JPM24 Thoughts

Plus more thinking on importation, 340B, and international pricing

Brian Reid
Brian Reid
Policy Talk Is Muted at #JPM24, But That Doesn't Mean Impacts Aren't Felt

Policy Talk Is Muted at #JPM24, But That Doesn't Mean Impacts Aren't Felt

And a Health Affairs paper adds further evidence that cost-sharing can be really, really bad for the public health

Brian Reid
Brian Reid
Even as #JPM24 Kicks Off in SF, the Pricing Conversation Remains Centered in DC

Even as #JPM24 Kicks Off in SF, the Pricing Conversation Remains Centered in DC

How Sanders & Co. deal with inhaler prices will be illuminating

Brian Reid
Brian Reid
Florida Gets FDA Go-Ahead to Try to Import Drugs from Abroad. Emphasis on 'Try'

Florida Gets FDA Go-Ahead to Try to Import Drugs from Abroad. Emphasis on 'Try'

Plus lots and lots about #JPM24, and why cost-plus is the new AI

Brian Reid
Brian Reid
FirstBack
1112131415161718
Next Last